Bioorthogonal Hydrogel Compositions for Delayed Drug Release
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Existing biomaterials for drug delivery exhibit an initial burst of activity after implantation and lack modularity, limiting their application in medical conditions requiring specific dosing regimens or delayed therapeutic agent administration.
Innovation Solution
Bioorthogonal compositions comprising hydrogel supports with complementary bioorthogonal functional groups and linkers allow for selective and controlled delivery of therapeutic agents to target locations, enabling modular and delayed release of payloads.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If systemic medications are used for treatment, then therapeutic agents can be delivered to the body, but frequent dosing is required and noxious side effects occur
Solution Approach 1:
The invention divides the therapeutic agent delivery into multiple components: a biomaterial depot that stores the agent and a delivery mechanism that releases it in a controlled manner over time, replacing frequent systemic dosing with a single implantation event
Solution Approach 2:
The biomaterial depot is implanted in advance at the target site, storing the therapeutic agent locally before it is needed, thereby eliminating the need for repeated systemic administration and reducing side effects
2Ease of manufacture
If existing biomaterials are used as depots for therapeutic agents, then agents can be released through diffusion or degradation, but the materials cannot be modulated or modified after implantation and exhibit an initial burst of activity
Solution Approach 1:
The invention introduces dynamic controllability to the biomaterial depot by incorporating stimuli-responsive elements that allow the release profile to be adjusted or modified after implantation based on physiological conditions or external triggers
Solution Approach 2:
The biomaterial depot is designed to perform multiple functions: initial drug storage, controlled release, and post-implantation modulation through various triggers, making it adaptable to different therapeutic scenarios and dosing requirements
3Productivity
If existing biomaterials are used as depots, then therapeutic agents can be delivered, but an initial burst of activity occurs shortly after implantation
Solution Approach 1:
The invention modifies the physical and chemical parameters of the biomaterial depot, such as crosslinking density, mesh size, and degradation rate, to control the release profile and eliminate the initial burst effect while maintaining sustained delivery
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The bioorthogonal compositions effectively deliver therapeutic agents to target locations with controlled release, enhancing treatment efficacy and reducing side effects by allowing for precise dosing and delayed administration.
Implementation Method 1
Bioorthogonal conjugation or click reactions are selective and orthogonal (non-interacting with) functionalities found in biological systems
Implementation Method 2
Existing biomaterials can serve as depots for therapeutic agents, which can be released to the body through diffusion or degradation
Data Source
AI summary
The present disclosure provides bioorthogonal compositions for delivering agents in a subject. The disclosure also provides methods of producing the compositions, as well as methods of using the same.